CN1259933C - 治疗冠心病的中药组合物及其制备方法和应用 - Google Patents
治疗冠心病的中药组合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN1259933C CN1259933C CN 200410024102 CN200410024102A CN1259933C CN 1259933 C CN1259933 C CN 1259933C CN 200410024102 CN200410024102 CN 200410024102 CN 200410024102 A CN200410024102 A CN 200410024102A CN 1259933 C CN1259933 C CN 1259933C
- Authority
- CN
- China
- Prior art keywords
- parts
- portions
- chinese medicine
- radix
- heart disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000029078 coronary artery disease Diseases 0.000 title claims abstract description 28
- 239000000203 mixture Substances 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims description 6
- 239000003814 drug Substances 0.000 claims abstract description 48
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 20
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 20
- 241000218176 Corydalis Species 0.000 claims abstract description 18
- 229940079593 drug Drugs 0.000 claims abstract description 10
- 239000000843 powder Substances 0.000 claims abstract description 10
- 241000628997 Flos Species 0.000 claims description 31
- 241000545442 Radix Species 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 3
- 239000004753 textile Substances 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 abstract description 15
- 230000036407 pain Effects 0.000 abstract description 15
- 239000008280 blood Substances 0.000 abstract description 14
- 210000004369 blood Anatomy 0.000 abstract description 14
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 11
- 230000017531 blood circulation Effects 0.000 abstract description 10
- 239000000341 volatile oil Substances 0.000 abstract description 6
- 230000002107 myocardial effect Effects 0.000 abstract description 5
- 230000036284 oxygen consumption Effects 0.000 abstract description 5
- 210000004204 blood vessel Anatomy 0.000 abstract description 4
- 239000003205 fragrance Substances 0.000 abstract description 4
- 230000006870 function Effects 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 4
- 230000004217 heart function Effects 0.000 abstract description 3
- 230000001939 inductive effect Effects 0.000 abstract description 2
- 230000000149 penetrating effect Effects 0.000 abstract description 2
- 241000173529 Aconitum napellus Species 0.000 abstract 2
- 241000758794 Asarum Species 0.000 abstract 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 1
- 241000427159 Achyranthes Species 0.000 abstract 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 abstract 1
- 244000020518 Carthamus tinctorius Species 0.000 abstract 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract 1
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract 1
- 235000019510 Long pepper Nutrition 0.000 abstract 1
- 240000003455 Piper longum Species 0.000 abstract 1
- 244000223014 Syzygium aromaticum Species 0.000 abstract 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 abstract 1
- 229940023019 aconite Drugs 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 229940116229 borneol Drugs 0.000 abstract 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- 238000002690 local anesthesia Methods 0.000 abstract 1
- 230000007721 medicinal effect Effects 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 description 12
- 239000009636 Huang Qi Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 238000010792 warming Methods 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000004087 circulation Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010061876 Obstruction Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 229930013930 alkaloid Natural products 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000000916 dilatatory effect Effects 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- -1 has analgesia Substances 0.000 description 3
- 210000000115 thoracic cavity Anatomy 0.000 description 3
- MJPMPMZXJIZPRE-UHFFFAOYSA-N 3-butyl-5,6,7,7a-tetrahydro-3h-2-benzofuran-1-one Chemical compound C1CCC=C2C(CCCC)OC(=O)C21 MJPMPMZXJIZPRE-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000001949 anaesthesia Methods 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 238000013475 authorization Methods 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 229940126678 chinese medicines Drugs 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical group COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 1
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- MQVRGDZCYDEQML-UHFFFAOYSA-N Astragalin Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(CO)O2)O)C(=O)C2=C(O)C=C(O)C=C2O1 MQVRGDZCYDEQML-UHFFFAOYSA-N 0.000 description 1
- WLYGSPLCNKYESI-RSUQVHIMSA-N Carthamin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@@]1(O)C(O)=C(C(=O)\C=C\C=2C=CC(O)=CC=2)C(=O)C(\C=C\2C([C@](O)([C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(O)=C(C(=O)\C=C\C=3C=CC(O)=CC=3)C/2=O)=O)=C1O WLYGSPLCNKYESI-RSUQVHIMSA-N 0.000 description 1
- DYQVDISPPLTLLR-HJQYTNQXSA-N Carthamin Natural products CC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@]2(O)C(=C(C=C/3C(=O)C(=C(O)[C@](O)([C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C3=O)C(=O)C=Cc5ccc(O)cc5)C(=O)C(=C2O)C(=O)C=Cc6ccc(O)cc6)O DYQVDISPPLTLLR-HJQYTNQXSA-N 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 206010016326 Feeling cold Diseases 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- 241000218628 Ginkgo Species 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 241001057584 Myrrha Species 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 1
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 206010062104 Renal mass Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- AXMVYSVVTMKQSL-UHFFFAOYSA-N UNPD142122 Natural products OC1=CC=C(C=CC=O)C=C1O AXMVYSVVTMKQSL-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229940039750 aconitine Drugs 0.000 description 1
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003260 anti-sepsis Effects 0.000 description 1
- 230000006502 antiplatelets effects Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 1
- 229940117916 cinnamic aldehyde Drugs 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- JPUKWEQWGBDDQB-QSOFNFLRSA-N kaempferol 3-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=CC(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O JPUKWEQWGBDDQB-QSOFNFLRSA-N 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明涉及一种治疗冠心病的中药组合物,其主要由以下重量组分的原料制成:川乌2~4份、细辛5~10份、荜茇10~15份、桂枝15~20份、丁香10~15份、川芎20~30份、红花15~20份、延胡索15~20份、三七5~10份、黄芪30~45份、牛膝15~20份和冰片3~6份。一般冠心病治疗单纯使用活血化瘀、扩张血管、增强心脏功能、减少心肌耗氧量的内服中药;本发明外用散剂,还使用了多种(牛膝、三七、川乌、细辛等)不宜(或慎用)内服的常规用于治祛风湿、散寒、局麻镇痛、止痛的外用药,再加上芳香、开窍,含挥发油,窜透力强的中药;配伍组合,协同增效,达到了较好的治疗冠心病效果。
Description
技术领域
本发明属于一种预防和治疗冠心病的药物组合物,具体涉及一种治疗冠心病的中药组合物,还涉及其制备方法和应用。
背景技术
冠心病的治疗,无论中医或是西医,基本上都是通过口服或注射给药。其发挥疗效或需通过胃肠道;或需通过血脑屏障;或是长期使用有不同的毒副作用;不太理想。
曾有将扩张冠状动脉的硝酸甘油,制成类似“伤湿止痛膏式”的橡胶硬膏——扩心贴片,敷贴于患者心前区作为防治冠心病的剂型;但与橡胶硬膏的情况类似,有引起皮肤过敏的现象,而使患者中止应用。
审定公告日1992年10月28日,审定号为CN1018792B,名称为《一种防治冠心病外用药的制作方法》,提出了一种“通过皮肤渗透作用不仅能治疗而且能预防冠心病的中成药的加工方法。”把具有活血化瘀、豁痰利湿、扩张血管、增强心脏功能、减少心肌耗氧量药性的中药和芳香开窍,走窜力强,能入心开窍并使毛细血营扩张的药物与三七粉和冰片粉面混合搅拌均匀。其具体的用量和制作方法如下:用重量百分比计,取4.3%(重量百分比)的玄参、5.8%的当归、4.3的决明子、4.3%的银杏叶、4.3%的郁金、5.1%的元胡、5.1%的红花、5.1%的没药、5.1%的乳番、5.1%的菖蒲、5.1%的花椒、5.1%的桂枝、5.1%的薤白、5.1%的瓜蒌、5.1%的党参、5.1%的黄芪、5.1%的降香、5.1%的夜交滕共18味中药,放低温干燥箱中,于摄氏50℃左右下干燥5小时,取出后放阴冷干燥处凉5小时,然后经粉碎机粉碎,过80目筛,弃渣留粉待用;取5.4%的冰片和5.3%的三七粉共同捣碾成粉面;最后将两者混合搅拌均匀即将产品。
其思路是对头的,但仍有不足:
1.药物的粒度粗,据其报道过80目筛;
2.用药品种太多,共20种;
3.所用药物,仍局限于内服煎剂中活血化瘀的常用中药范畴。
发明内容
本发明的目的,是在另一种思路的基础上,提供有别于现有技术的一种治疗冠心病的中药组合物及其制备方法和应用。
本发明采用的技术方案是:研制一种治疗冠心病的中药组合物,其特征是主要由以下重量组分的原料制成:
川乌2~4份、细辛5~10份、荜茇10~15份、桂枝15~20份、丁香10~15份、川芎20~30份、红花15~20份、延胡索15~20份、三七5~10份、黄芪30~45份、牛膝15~20份和冰片3~6份。
本发明中药组合物,其中各原料的优选重量组分是:
川乌2~3份、细辛8~10份、荜茇10~12份、桂枝18~20份、丁香10~12份、川芎20~22份、红花18~20份、延胡索18~20份、三七5~7份、黄芪30~35份、牛膝18~20份和冰片3~4份。
本发明中药组合物,其中各原料的最佳重量组分是:
川乌2份、细辛10份、荜茇10份、桂枝20份、丁香10份、川芎20份、红花20份、延胡索20份、三七5份、黄芪30份、牛膝20份和冰片3份。
上述的药用组合物的剂型是散剂。
上述的治疗冠心病的中药组合物的制备方法,按配量称取上述诸药物,置入研磨器械中,共研细至粒度均匀达≤74~149μm,装入透气的纺织品袋中,制成挥发性药物袋备用。
上述的药用组合物在制备预防和治疗冠心病的外用散剂中的应用。
按照中医理论,冠心病的病机为血瘀、气滞、寒凝阻阳之胸痹症。本发明共使用12味中药,其中:本发明技术方案中君为川乌、川芎、三七;取其活血化瘀、行气、散寒、止痛之功效。臣为细辛、荜茇、桂枝、红花、延胡索;除加强君药之功力外还用其温阳通经之功效。佐为黄芪、冰片;用其固表益气调和诸药防腐杀菌之功力。使为丁香、牛膝用其芳香开窍行气引药入经之功效。故本发明技术方案具有芳香通阳,益气化瘀,散寒止痛之功效。外用散剂剂型能加大药量增加功效而避免不良反应;可用于冠心病的各种类型。
本发明技术方案中:
川乌:入心、脾经。祛风湿、散寒、止痛。辛热、有大毒。
现代研究,乌头碱具有局麻镇痛及抗炎作用,可以使心率减慢,安全范围小,内服宜慎。
细辛:入心、肾经。辛、温;祛风散寒,止痛,温肺化饮宣窍。
现代研究含挥发油,具有镇痛,局麻作用,内服不超3克。
荜茇:辛、热、入脾肾经。温中散寒,下气止痛。
现代研究其挥发油对实验性心肌缺血有明显对抗作用,并能预防多种试验性心律失常。
桂枝:辛、甘、温。入肺、心、膀胱经。发汗解肌,温经通阳,平冲降逆。治风寒感冒,风湿痹痛痛经、脘腹冷痛,闭经,痰饮咳喘,胸痹心悸,奔豚,水肿,小便不利。
现代研究:本品挥发油,主为桂皮醛,有利胆、解痉,镇静、解热作用。
丁香:辛、温。入胃、脾、肾经。温中降逆,暖肾助阳。
现代研究主要成分为丁香油酚,为芳香健胃剂,增强消化能力,减轻恶心呕吐。
川芎:辛、温。入肝、胆、心包经。活血行气,散风止痛。
现代研究本品含挥发油,生物碱,川芎内酯等,能降低血压,增加冠脉血流量,降低冠脉阻力,抑制血栓形成及血小板的凝聚,对已形成的凝聚块有解聚作用。生物碱有抗急性心肌缺血、缺氧作用,并能提高心肌对缺氧的耐受力。
红花:辛、温。入心、肝经。活血通经,去瘀止痛。
现代研究含红花甙等,有降压作用,提取物能增加狗的冠脉流量,改善冠脉循环,缩小心肌梗死面积降低心肌耗氧量有关,能对抗离体血管对去甲肾上腺素的收缩作用。
延胡索:苦、微辛,温。入肝、胃经。活血、行气,止痛。
现代研究含延胡索素等多种生物碱,有镇静,止痛作用,并还有降低血压及抗心律失常作用。
三七:甘、微苦、温。入肝、胃经。止血,散瘀、止痛。
现代研究含人参皂甙、三七皂甙、黄酮甙,能增加动物的冠脉血流量,对抗垂体后叶素引起的冠脉流量减少降低心肌耗氧量,对离体蛙心有强心作用,对狗有降压、利尿作用,抗血小板作用。对实验性血栓形成有防治作用。
黄芪:甘、微温。入脾、肺经。补中益气,固表,利水,托脓毒,生肌。
现代研究含黄芪甙,香豆素等,在人及动物身上均能利尿,增强机体抵抗力,抗自由基损伤和抗脂质过氧化作用。对动物能降低血压,扩张血管。毒性很低。
牛膝:苦、酸、平。入肝,肾经。活血、行瘀、消肿。
现代研究含三萜皂甙、谷甾醇等,对狗、兔有短暂降压和轻度利尿作用。并能抑制心脏和肠管的收缩。
冰片:苦、辛、凉。入心、肺经。散瘀,清热止痛,防腐。
与现有技术比较,本发明的优点是:
1.一般冠心病治疗单纯使用活血化瘀、扩张血管、增强心脏功能、减少心肌耗氧量的内服中药。
本发明技术方案组方中,不仅使用活血化瘀的内服中药,还使用了多种(例如,牛膝、三七、川乌、细辛等)不宜(或慎用)内服的常规用于治祛风湿、散寒、局麻镇痛、止痛的外用药,再加上芳香、开窍,含挥发油,窜透力强的中药;配伍组合,协同增效,达到了较好的治疗冠心病效果。
2.药物的粒度细,药物散剂研细至粒度达≤74~149μm。
3.用药少而精,仅用共12种。
临床效果
经在山东淄博市桓台县人民医院,对15例西医药物治疗疗效不佳的确诊冠心病患者,在继续药物治疗的基础上同时给以本发明技术方案的外用散剂(临床验证时,曾用名“心宁宝”)试用,结果13例在应用后出现显著效果,平均显效时间5至10天,症状改善不明显2例,有效率86.6%;心电图改善率66.6%;均未出现不良反应。
患者自觉症状胸闷、心前隐痛明显改善或消失,睡眠改善,心电图明显或有所改善,血流变检查中血液粘度明显或有所下降。
具体实施方式
以下结合实施例对本发明作进一步阐述:
实施例1
重量组成:
川乌2g、细辛10g、荜茇10g、桂枝20g、丁香10g、川芎30g、红花15g、延胡索20g三七5g、黄芪45g、牛膝15g和冰片6g。
炮制:按配量称取上述诸药物,置≤50℃烘箱中干燥4h,晾至室温后入研磨机中研磨,98%通过200目筛,筛后细粉装入细棉布袋中。
上述的药用组合物在制备预防和治疗冠心病的外用散剂中的应用。
制成挥发性药物袋,固定在左前胸部(心前区),七至十日更换一次。
本发明外用散剂,能芳香通阳、益气化瘀、散寒止痛;对冠心病心绞痛、心肌梗死和其他胸痹症有预防和治疗效果。
实施例2
重量组成:
川乌4g、细辛5g、荜茇15g、桂枝15g、丁香15g、川芎20g、红花20g、延胡索15g、三七10g、黄芪30g、牛膝20g和冰片3g。其余同实施例1。
实施例3
重量组成
川乌3g、细辛7g、荜茇13g、桂枝17g、丁香12g、川芎22g、红花17g、延胡索20g、三七9g、黄芪40g、牛膝20g和冰片6g。其余同实施例1。
实施例4
重量组成:
川乌2g、细辛8g、荜茇13g、桂枝18g、丁香13g、川芎25g、红花18g、延胡索18g、三七8g、黄芪35g、牛膝18g和冰片5g。其余同实施例1。
实施例5
重量组成:
川乌4g、细辛6g、荜茇15g、桂枝15g、丁香15g、川芎20g、红花20g、延胡索15g、三七10g、黄芪30g、牛膝20g和冰片3g。其余同实施例1。
实施例6
重量组成
川乌3g、细辛7g、荜茇12g、桂枝17g、丁香14g、川芎28g、红花15g、延胡索20g、三七9g、黄芪40g、牛膝20g和冰片6g。其余同实施例1。
实施例7
重量组成:
川乌4g、细辛8g、荜茇10g、桂枝20g、丁香10g、川芎30g、红花16g、延胡索18g、三七5g、黄芪35g、牛膝15g和冰片3g。其余同实施例1。
Claims (6)
1.一种治疗冠心病的中药组合物,其特征是由下述重量份的组分组成:
川乌2~4份、细辛5~10份、荜茇10~15份、桂枝15~20份、丁香10~15份、川芎20~30份、红花15~20份、延胡索15~20份、三七5~10份、黄芪30~45份、牛膝15~20份和冰片3~6份。
2.按照权利要求1所述的治疗冠心病的中药组合物,其特征是由下述重量份的组分组成:川乌2~3份、细辛8~10份、荜茇10~12份、桂枝18~20份、丁香10~12份、川芎20~22份、红花18~20份、延胡索18~20份、三七5~7份、黄芪30~35份、牛膝18~20份和冰片3~4份。
3.按照权利要求1所述的治疗冠心病的中药组合物,其特征是由下述重量份的组分组成:
川乌2份、细辛10份、荜茇10份、桂枝20份、丁香10份、川芎20份、红花20份、延胡索20份、三七5份、黄芪30份、牛膝20份和冰片3份。
4.按照权利要求1、2或3所述的治疗冠心病的中药组合物,其特征是所述的药用组合物的剂型是散剂。
5.按照权利要求1、2或3所述的治疗冠心病的中药组合物的制备方法,其特征是按配量称取上述诸药物,置入研磨器械中,共研细至粒度均匀达≤74~149μm,装入透气的纺织品袋中,制成挥发性药物袋备用。
6.按照权利要求1、2或3所述的治疗冠心病的中药组合物,其特征是所述的中药组合物在制备预防和治疗冠心病的外用散剂中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410024102 CN1259933C (zh) | 2004-05-13 | 2004-05-13 | 治疗冠心病的中药组合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410024102 CN1259933C (zh) | 2004-05-13 | 2004-05-13 | 治疗冠心病的中药组合物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1569172A CN1569172A (zh) | 2005-01-26 |
CN1259933C true CN1259933C (zh) | 2006-06-21 |
Family
ID=34480486
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410024102 Expired - Fee Related CN1259933C (zh) | 2004-05-13 | 2004-05-13 | 治疗冠心病的中药组合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1259933C (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101869689B (zh) * | 2010-06-22 | 2011-12-14 | 杨丽华 | 治疗心绞痛型冠心病的外用中药组合物 |
CN102772590B (zh) * | 2012-07-23 | 2014-03-12 | 广东省中医院 | 一种中药组合物及凝胶膏剂和制备方法 |
CN106491958B (zh) * | 2015-09-08 | 2020-04-17 | 上海中医药大学附属曙光医院 | 治疗冠心病心绞痛的中药复方制剂及其制备方法 |
CN108434288A (zh) * | 2018-06-18 | 2018-08-24 | 马南行 | 一种用于心脏病预防和治疗的组合物 |
-
2004
- 2004-05-13 CN CN 200410024102 patent/CN1259933C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1569172A (zh) | 2005-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1061854C (zh) | 治疗、预防妇科疾患的药物制剂 | |
CN102671130B (zh) | 一种抗肿瘤的中药 | |
CN103356973B (zh) | 一种抗肿瘤的中药 | |
CN103520680B (zh) | 治疗急性心衰的中药 | |
CN1876053A (zh) | 一种用于艾灸的药物及其制备方法 | |
CN1047090C (zh) | 治疗气管炎、肺炎的中药贴剂 | |
CN102579610B (zh) | 一种治疗脑出血的中药组合物及其制备方法 | |
CN101204552A (zh) | 一种治疗乳腺癌和宫颈癌的中药组合物及其制备方法 | |
CN102940751B (zh) | 一种跌打活血滴丸及其制备方法 | |
CN1259933C (zh) | 治疗冠心病的中药组合物及其制备方法和应用 | |
CN101274024A (zh) | 一种治疗牙疼的药物组合物 | |
CN103623280A (zh) | 一种治疗心脑血管疾病的中药制剂 | |
CN101983695A (zh) | 一种治疗半身不遂的中药组合物及其制备方法 | |
CN1049586C (zh) | 骨质增生外敷剂及其制法 | |
CN1899482A (zh) | 一种治疗慢性肾小球肾炎的药物及其制取方法 | |
CN1465387A (zh) | 一种治疗食管癌的中药制剂 | |
CN101297954B (zh) | 治疗咳嗽的敷脐药物及制备方法 | |
CN1241598C (zh) | 一种治疗牙周病的中药制剂、制备方法及应用 | |
CN100398143C (zh) | 一种治疗白癜风的药剂 | |
CN1244335C (zh) | 抗流感药物 | |
CN102764275A (zh) | 一种治疗肿瘤的外用中药及其制备方法 | |
CN103028079A (zh) | 一种预防和治疗脑肿瘤的药物组合物及其制备方法 | |
CN101912476A (zh) | 治疗妇女月经过多病症的中草药 | |
CN1340350A (zh) | 面瘫咀嚼剂及其制备方法 | |
CN103230490B (zh) | 一种治疗肝肿瘤的中药散剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |